Feb 28,2022

Reducing dose frequency may help improve asthma medication adherence

Findings from a Propeller Health study recently published in The Journal of Allergy and Clinical Immunology demonstrated that patients with asthma who are prescribed once-daily dosing schedules are more likely to adhere to their controller medications than those with twice-daily prescriptions. The percentage of patients who achieved greater than 80% adherence was also significantly higher for once-daily users compared to twice-daily users, with once-daily users being 1.4 times as likely to achieve high medication adherence as twice-daily users.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Mar 01,2022

New Study Finds Cancer-Related Anxiety and Depression are Costing Medicare $5B Annually

Blue Note Therapeutics announces findings of new study highlighting the financial impacts of cancer-related anxiety and depression in Medicare beneficiaries. The study, which included over 230,000 Medicare patients, found that the incremental healthcare costs of cancer-related anxiety and depression are estimated to be nearly $17,500 per patient annually. This corresponds to a greater than 75 percent premium on the cost of cancer care for patients with anxiety and depression compared to those without.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Mar 09,2022

Omada Health Insights Lab Report Uncovers that Omada Health Programs Can Improve Mindsets in Three Weeks

Omada Health, a chronic care integrated healthcare provider, announces today at Mindset Summit 2022 breaking data from the Omada Health Insights Lab. The report, powered by Omada Insights Lab in collaboration with Dr. Alia Crum, investigated whether Omada Health’s virtual Diabetes Prevention Program (DPP) could change participants’ mindsets and was associated with better health outcomes. The findings of the report show mindset change can, in fact, be linked to health outcomes as early as week three of starting the program.

CLINICAL STUDY

#coaching

View Analyst & Ambassador Comments
Go to original news
Mar 11,2022

Click Therapeutics Provides Research and Development Updates on Its Click Neurobehavioral Intervention (CNI) Platform

Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics as prescription medical treatments, announced updates from multiple early research and development (R&D) studies across its Click Neurobehavioral Intervention (CNI) Platform.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Mar 15,2022

Better Therapeutics Announces Positive Primary Endpoint Data From Pivotal Clinical Trial of BT-001 for Patients With Uncontrolled Type 2 Diabetes

Better Therapeutics, Inc. (“Better Therapeutics”, NASDAQ: BTTX), a prescription digital therapeutics company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced primary endpoint data from its pivotal trial of BT-001, a first-in-class investigational PDT platform that is designed to use digitally delivered nCBT to treat type 2 diabetes. The primary efficacy endpoint (n=602) showed highly statistically significant improvement in A1c between the intervention and control groups. There was a clear dose-response between greater engagement in nCBT and greater reductions in A1c, supporting nCBT as a mechanism of action.

CLINICAL STUDY

#pdt

#cbt

View Analyst & Ambassador Comments
Go to original news
Mar 15,2022

Pear Therapeutics Announces Data from Two Studies Evaluating Prescription Digital Therapeutics (PDTs) for Chronic Insomnia Presented at World Sleep Congress 2022

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced data that further underscore the effectiveness of Somryst®, the only FDA-authorized PDT for the treatment of chronic insomnia. Interim data showed, by end of treatment, 78.7% and 73.3% of participants treated with Somryst achieved the American Academy of Sleep Medicine (AASM) clinically meaningful definition of sleep onset latency remission. Final results were presented in a symposia at World Sleep 2022, the international Congress of World Sleep Society, on March 15 in Rome, Italy.

CLINICAL STUDY

#pdt

#mobile app

View Analyst & Ambassador Comments
Go to original news
Mar 28,2022

A Smartphone-Based Intervention as an Adjunct to Standard-of-Care Treatment for Schizophrenia: Randomized Controlled Trial

Antipsychotic medications have limited benefits in schizophrenia, and cognitive behavioral therapy may be beneficial as an adjunct. There may be potential for implementing mobile cognitive behavioral therapy–based treatment for schizophrenia in addition to standard antipsychotic medications. This study aims to determine whether PEAR-004, a smartphone-based investigational digital therapeutic, improves the symptoms of an acute psychotic exacerbation of schizophrenia when it is added to standard treatments.

CLINICAL STUDY

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
Apr 06,2022

Better Therapeutics Announces Key Milestones and Updates for Ongoing Studies of its Digital Therapeutics Approach for Cardiometabolic Diseases

Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced several key research milestones designed to advance and further validate its therapeutic technologies, including the first ever study of nCBT as potential treatment for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH).

CLINICAL STUDY

#pdt

#cbt

View Analyst & Ambassador Comments
Go to original news
Apr 06,2022

New Propeller Health data on patient behavior to be revealed at SBM 2022

Research continues to show how positive behavior change can play an important role in improving health outcomes, especially among patients with chronic conditions such as asthma and COPD. With three peer-reviewed abstracts accepted for presentation at the Society of Behavioral Medicine (SBM) 2022 Annual Meeting on April 6-9, Propeller Health’s recent findings on patient behavior – as they relate to the pandemic, digital health use and smoking prevalence – add to this growing body of knowledge.

CLINICAL STUDY

#mobile app

#connected device

View Analyst & Ambassador Comments
Go to original news
Apr 08,2022

Happify Releases Results of Its Real-World Psoriasis Data

Digital therapeutic company Happify released results of its real-world psoriasis data analysis. Researchers found that patients with psoriasis who completed 16 Happify activities within a minimum of six weeks reported a 27% reduction in anxiety symptoms and a 27% boost in subjective wellbeing. Meanwhile, the study reports that individuals who completed less than 16 activities improved their wellbeing score by 4.11% and reduced their anxiety score by 8.15%.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY